Lv58
1100 积分 2022-10-31 加入
Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases
4天前
已完结
Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer
4天前
已完结
Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline BRCA1/2-Mutated Breast Cancers in the High-Risk, Early-Stage Setting
4天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
7天前
已完结
Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low
11天前
已完结
VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
11天前
已完结
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
11天前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
11天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
12天前
已完结
Antibody–Drug Conjugates in breast cancer
12天前
已完结
皖公网安备34019202002308
